GlassScriptPhysician profile
Hussain Al-Darsani
NPI 1669429775
$4,917.27
in general payments reported to CMS, 2019-2025
28 companies · $876 in 2025
The $876 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $804 · 2020: $169 · 2021: $312 · 2022: $803 · 2023: $1,156 · 2024: $797 · 2025: $876.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,829.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,829.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $610.68 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Celgene Corporation | $519.86 | 2022-2024 | Zeposia |
| Abbvie INC. | $466.17 | 2022-2025 | Linzess, Viberzi, Rinvoq |
| Ferring Pharmaceuticals INC. | $455.00 | 2019-2023 | Rebyota |
| Gilead Sciences, INC. | $408.10 | 2019-2025 | |
| Phathom Pharmaceuticals, INC. | $281.04 | 2024-2025 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $258.57 | 2019-2021 | |
| Madrigal Pharmaceuticals | $234.68 | 2024-2025 | Rezdiffra, Resmetirom |
| Ardelyx, INC. | $204.40 | 2022-2025 | Ibsrela |
| Redhill Biopharma INC. | $165.70 | 2021-2023 | Talicia |
| Allergan, INC. | $162.26 | 2019 | |
| Janssen Biotech, INC. | $159.31 | 2022-2024 | Stelara, Simponi, Simponi Aria |
| Pfizer INC. | $155.44 | 2022-2025 | |
| Braintree Laboratories, INC. | $118.94 | 2022-2025 | Suflave, Sutab |
| Janssen Pharmaceuticals, INC | $114.92 | 2019-2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $98.45 | 2019-2025 | Ocaliva |
| Novo Nordisk INC | $89.87 | 2025 | Wegovy |
| Merck Sharp & Dohme LLC | $74.66 | 2019-2023 | Dificid |
| Qol Medical, LLC | $71.23 | 2024-2025 | Sucraid, Sucraid |
| Genzyme Corporation | $55.84 | 2022-2023 | |
| Albireo Pharma, INC. | $48.41 | 2024 | Iqirvo |
| Ironwood Pharmaceuticals, INC | $41.76 | 2020-2023 | Linzess |
| Shionogi INC | $26.43 | 2019 | |
| Xeris Pharmaceuticals, INC. | $24.82 | 2023 | Keveyis |
| Alnylam Pharmaceuticals INC. | $20.43 | 2025 | Givlaari |
| Evoke Pharma, INC. | $19.09 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $16.15 | 2024 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $15.06 | 2023 | Arazlo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hussain Al-Darsani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.